BioAge Labs Initiates Phase 1 Clinical Trial for BGE-102, a Brain-Penetrant NLRP3 Inhibitor Targeting Obesity
Reuters
Aug 15
BioAge Labs Initiates Phase 1 Clinical Trial for BGE-102, a Brain-Penetrant NLRP3 Inhibitor Targeting Obesity
BioAge Labs Inc., a clinical-stage biotechnology company, has announced the commencement of a Phase 1 clinical trial for BGE-102, an innovative, orally available small molecule inhibitor of NLRP3. This novel inhibitor demonstrates potential for significant brain penetration and is initially being developed for obesity treatment. The study, which marks the first human dosing of BGE-102, aims to evaluate the drug's safety, tolerability, pharmacokinetics, and pharmacodynamics. Preclinical models have shown promising results, highlighting robust weight loss when BGE-102 is used as a monotherapy or in combination with GLP-1 receptor agonists. BioAge Labs anticipates initial data from the study's single ascending dose (SAD) phase by the end of 2025. The company plans to conduct a proof-of-concept study in 2026, with top-line results expected by the end of that year.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioage Labs Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9513066-en) on August 15, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.